Venous thromboembolism with contraceptive use in females with sickle cell trait
Although there was a small number of venous thromboembolism events, the findings of this study suggest that the use of combined hormonal contraceptives in females with sickle cell trait is not associated with a detectable signal for increased venous thromboembolism risk as an outcome. Given the potential clinical benefit of combined hormonal contraceptives in pregnancy prevention and menstrual regulation in females, the concerns about combined hormonal contraceptive-associated venous thromboembolism in this population with sickle cell trait seem to be minimal.
Authors
- Anwar Ahmed (ORCID: https://orcid.org/0000-0001-8743-6007)
- Candy Wilson (ORCID: https://orcid.org/0000-0001-5913-1521)
- Margaret Bevans (ORCID: https://orcid.org/0000-0003-0448-2011)
- Arun S. Shet (ORCID: https://orcid.org/0000-0002-4146-0703)
- Angela K Phillips (ORCID: https://orcid.org/0000-0002-1843-2982)
Institutions
- United States Army Medical Command (US)
- Uniformed Services University of the Health Sciences (US)
- National Heart, Lung, and Blood Institute (US)
- Florida Atlantic University (US)
Publication Details
- Journal
- AJOG Global Reports
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1016/j.xagr.2025.100497
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00